In a preliminary study, we showed that the breast cancer multi-drug resistance (MDR) cell line MCF-7/ADR, which is derived from the MCF-7 cell line by selection for growth in increasing concentrations of adriamycin, expresses lower levels of Cbl-b (Figure 3C) than MCF-7 cells. The gene discussed is CBLB; the disease is breast carcinoma.